| This week's sponsor is Premier Research. | | | Beyond Intensity: The Full Impact of Fibromyalgia Pain
Patient-reported outcomes drive fibromyalgia drug research, and pain intensity is one measure of many. Download our white paper to gauge the many related symptoms. Premier Research. It's what we do. Best. |
Today's Rundown Lilly scraps rheumatoid arthritis trial after interim review Aimmune aces peanut allergy phase 3, teeing up FDA filing Ionis farms out antisense drug to AstraZeneca in deal worth up to $330M [Sponsored] Optimizing Humanized Model Selection for Enhanced Preclinical Immunotherapy Assessment AbbVie doubles down on tau with Voyager Alzheimer's deal Takeda rides the neuro R&D Wave with latest biotech pact Shire, Microsoft ally to accelerate diagnosis of rare diseases AstraZeneca's Imfinzi breaks new I-O ground with landmark $1B lung cancer nod Featured Story | | | Tuesday, February 20, 2018 Eli Lilly has halted a phase 2 rheumatoid arthritis trial after getting a midstudy glimpse at the data. The setback leaves Lilly and partner Hamni Pharmaceutical to weigh whether it is worth moving the Bruton's TKI forward in other indications. |
|
|
| This week's sponsor is NYCEDC. | | | |
Top Stories Tuesday, February 20, 2018 Aimmune has presented strong data from a phase 3 trial of its peanut allergy treatment AR101. The Brisbane, California-based biotech plans to file for FDA approval by the end of 2018 to give patients a way to protect themselves against accidental exposure to peanut protein. Tuesday, February 20, 2018 Ionis Pharmaceuticals has licensed an antisense drug for the treatment of kidney disease to AstraZeneca, picking up a $30 million payment in the process. Tuesday, February 20, 2018 Tumor-bearing humanized models are vital preclinical platforms for assessing human-specific immunotherapies. Review immediately transferable humanized model strategies for accelerating immunotherapy drug discovery programs. Tuesday, February 20, 2018 AbbVie has teamed up with Voyager Therapeutics on a tau protein-targeting program, paying $69 million upfront for an option on the Alzheimer’s disease candidate. Tuesday, February 20, 2018 Perennial biotech dealmaker Takeda is at it again, striking a new pact with Wave Life Sciences with a focus on a series of difficult-to-treat neurological disorders. Tuesday, February 20, 2018 Shire and Microsoft have joined forces to cut the time it takes to diagnose rare diseases in children. The companies are part of a star-studded commission that is working on a road map for improving outcomes in rare diseases. Tuesday, February 20, 2018 Backed by convincing survival data, AstraZeneca’s Imfinzi is breaking out on its own. The drug snagged an FDA green light in previously treated lung cancer patients whose tumors can't be surgically removed, a market without a single competitor in sight. | This week's sponsor is ExL Events. | | | |
Resources Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Presented by: Box and USDM Life Sciences Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process. Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA PEGS: The Essential Protein Engineering Summit April 30-May 4 | Boston, MA Partnering for Growth 2018 March 20th | 7:30 am-6 pm
March 21st | 7:30 am-1:15 pm Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 